Clene Inc. (NASDAQ:CLNN) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Clene Inc. (NASDAQ:CLNN) have received a consensus recommendation of “Moderate Buy” from the seven research firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $33.25.

CLNN has been the topic of a number of recent research reports. D. Boral Capital reissued a “buy” rating and set a $23.00 price target on shares of Clene in a research note on Monday, May 4th. HC Wainwright reiterated a “buy” rating and set a $31.00 target price on shares of Clene in a research report on Monday, May 4th. Roth Capital reissued a “buy” rating on shares of Clene in a report on Thursday, May 14th. Finally, Weiss Ratings upgraded shares of Clene from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday.

Insider Buying and Selling at Clene

In related news, major shareholder Chidozie Ugwumba sold 73,296 shares of the stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $6.20, for a total value of $454,435.20. Following the completion of the sale, the insider directly owned 103,417 shares in the company, valued at $641,185.40. This represents a 41.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold a total of 259,312 shares of company stock valued at $1,650,432 over the last quarter. Insiders own 28.30% of the company’s stock.

Institutional Investors Weigh In On Clene

A number of institutional investors have recently made changes to their positions in CLNN. SymBiosis Capital Partners LLC acquired a new stake in shares of Clene in the fourth quarter valued at about $4,523,000. Scoggin Management LP lifted its stake in shares of Clene by 75.1% in the third quarter. Scoggin Management LP now owns 250,000 shares of the company’s stock worth $1,506,000 after acquiring an additional 107,250 shares during the period. Ensign Peak Advisors Inc boosted its holdings in Clene by 668.6% in the fourth quarter. Ensign Peak Advisors Inc now owns 114,361 shares of the company’s stock valued at $671,000 after acquiring an additional 99,481 shares during the last quarter. PEAK6 LLC bought a new stake in Clene in the fourth quarter valued at approximately $294,000. Finally, State Street Corp increased its position in Clene by 138.4% during the 4th quarter. State Street Corp now owns 29,801 shares of the company’s stock valued at $175,000 after purchasing an additional 17,300 shares during the period. Institutional investors own 23.28% of the company’s stock.

Clene Stock Performance

Shares of NASDAQ:CLNN opened at $5.69 on Friday. Clene has a 52-week low of $3.25 and a 52-week high of $13.50. The company has a market capitalization of $72.72 million, a PE ratio of -1.78 and a beta of 0.92. The company has a fifty day moving average of $6.18 and a 200-day moving average of $5.69.

Clene (NASDAQ:CLNN) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.05). The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.05 million. On average, equities analysts forecast that Clene will post -1.58 EPS for the current fiscal year.

Clene Company Profile

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).